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SUMMARY
A procedure to attenuate live influenza virus of type A and type B was developed using
adaptation of the virus to grow at 25C (cold adaptation; ca). Through a series of stepwise
passages, two stable mutants were obtained and designated as ‘Master’ strains, one for type A
influenza virus (A/Ann Arbor/6/60-H2N2) and one for type B influenza virus (B/Ann
Arbor/1/66). These mutants were used in genetic reassortment using either the classical method
or more recently described reverse genetics to update the relevant surface antigens of the
circulating strains of influenza virus. The derivation is based on the concept of 6/2 where 6
signifies the six internal genes of the master strain and 2 refers to the two genes coding for the
two surface glycoproteins HA and NA of the circulating influenza virus. The advantages of this
vaccine were demonstrated to be (1) proper level of attentuation, (2) non-transmissibility, (3)
genetic stability, (4) presence of the ca and ts markers and (5) immunogenicity involving both
local and the cell-mediated immune responses. The clinical trials in infants, children, adults and
elderly have provided the necessary data for eventual licensing of this vaccine. The ease of
administration (intranasal) safety and high efficacy make this vaccine suitable to prevent
influenza virus infection in all age groups. Copyright  1999 John Wiley & Sons, Ltd.
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INTRODUCTION
Prophylaxis of influenza virus has been a recurring public
health concern for many years with frequent reexamin-
ation of variable vaccines and policies for their use.
Outbreaks and epidemics of influenza virus type A and B
exhibit definite excess mortality (especially among the
elderly) and considerable morbidity (especially among
school-age children) which are regularly observed during
the influenza season. In the case of a disease such as
influenza, it has become recognised that antigenic
changes in the causative viruses impose a profound
handicap to the development of a sound system of
immunisation. The time factor alone (14 days) hasCCC 1052–9276/99/040237–08$17.50
Copyright 1999 by John Wiley & Sons, Ltd.suggested that inactivated vaccine will never suffice to
provide the limitation in the transmission of virus which
could furnish the power to prevent epidemic spread. For
these reasons, research and clinical testing is continuing
with the aim of identifying an effective and safe live
influenza virus vaccine for use in humans.1–6
HISTORICAL BACKGROUND
The approach to prevention of influenza by vaccination is
based on several observations. First, recovery from infec-
tion is accompanied by antibody development and resist-
ance to reinfection. Second, in experimental animals
antibody production and immunity can be induced by
para respiratory injection of active or inactive virus.
Third, circulating antibody levels similar to those
observed in convalescence can be obtained in humans by
vaccination, presumably reflecting an accompanying
immunity. Vaccination enhances the neutralising capacity
of nasal secretions in man, thus providing increased
protection to the susceptible cells of the respiratory*Correspondence to: Dr H. F. Maassab, Department of Epidemiology,
School of Public Health, University of Michigan, 109 Observatory
Street, Ann Arbor, Michigan 48109, USA.
Abbreviations used: ca, cold-adapted; CAIV-T, cold-adapted influ-
enza vaccine-trivalent; CR, cold-reassortant; FDA, Federal Drug
Administration; Ha, haemagglutinin; IgA, immune globulin A; PCKC,
Primary chick kidney cells; Na, neuraminidase; NIH, National
Institutes of Health; PFU, plaque forming unit; SPAFAS, pathogen-
free; ts, temperature sensitive; vac, vaccine.
LIVE INFLUENZA VIRUS VACCINE 239mucosa. Vaccination has been shown to prevent the
severe viral pneumonia produced in ferrets by well-
adapted strains of virus even though intranasal
challenge may induce fever and damage to the ciliated
epithelium,7,8
A number of early studies with active or inactive virus
from various sources demonstrated that vaccines were
immunogenic in humans, but the results of field prophy-
laxis were inconsistent, owing partly to low incidence of
disease, inconstant potency of vaccine and strain vari-
ation. The incidence of disease in the vaccinated was
inversely related to the level of circulating antibody to
the epidemic strain; this observation has been well
substantiated.9 The effect of vaccine became evident 7 to
10 days after administration. In some of the study units
streptococcal infections were prevalent at the time influ-
enza appeared, without creating significant complications.
Other observations indicated that influenza was signifi-
cantly reduced in institutional populations vaccinated a
year earlier. The ability of vaccines to reduce severity of
illness has been shown in experimental animals and in
induced infections of human. On this basis it might be
expected that even though moderate fever and local
respiratory signs might occur, circulating antibodies
would reduce the likelihood of lower respiratory
involvement.10–13
Based on the knowledge of strain variation and the
variation in antibody patterns of the different age groups
in the population, a continued objective has been to
create a vaccine containing a pool of antigens including
those known to have been prominent in epidemic strains
of influenza virus. Moreover, secondary antigens con-
tained within such a compound vaccine could potentially
stimulate a broad antibody response against a wide range
of other strains, just as human sera may, after repeated
infections, contain antibody to strains which have not yet
been encountered epidemically by the younger age
groups. The 1957 experience emphasised that the domi-
nant antigen of an earlier strain may return to epidemic
circulation when the population loses its immunity by
aging, death and a growing replacement by suscepti-
bles.8,14,15 A compound vaccine could also provide
conditioning to varied antigens early in life which could
be boosted promptly by subsequent vaccination to estab-Copyright  1999 John Wiley & Sons, Ltd.lish an enhanced broad resistance rather than acquiring it
by repeated infections. Obviously, this approach requires
a comprehensive immunologic effort and flexibility in
formulation of vaccines, but present knowledge suggests
it has a reasonable potential for addressing the great
antigenic variability in influenza viruses.16–18
Limitations to this approach include the fact that
vaccine does not prevent respiratory disease caused by
other pathogens and by exaggerated talk of reactions.
The duration of protection is not fully established, and
annual vaccination is an inconvenience. Production of
vaccine has not been sufficiently great to permit uniform
vaccination annually. With consideration of the above
factors, the Surgeon General’s United States Public
Health Service Advisory Committee on Influenza recom-
mended annual vaccination of certain groups of persons
shown by experience to be at high risk of severe or fatal
illness with influenza.19–22
Epidemics may be so extensive as to disrupt normal
community operation and strain its facilities. Conse-
quently, personnel of community services—medical and
health, utilities, safety, education and communications—
should be protected. Vaccination of groups of industrial
workers has been shown to be of benefit.5 The families of
the people listed in Table 1, especially young children,
could also benefit from vaccination, emphasising that
influenza vaccine ought ordinarily to be considered for
group administration.23,24 Vaccinations of school popu-
lations would serve to reduce the large impact which that
segment of the population contributes to the community
load of illness and its dissemination. The family can be
considered the basic group for action. Thus, with the
probability of epidemic involvement, no group is exempt
from consideration at the community level. Vaccine has
been used uniformly in the military of the United States
for an extended period. The advantages are seen in the
low incidence of disease in service units and installations
when high levels are occurring in civilian populations. For
example, in 1960, little or no epidemic influenza was
detected in posts under close surveillance, while the
civilian epidemic was pronounced.25
Another area of advance has been the demonstration
that preparations of purified viral haemagglutinin are as
effective as whole virus in the stimulation of antibody inTable 1. Characteristics of persons considered high risk
1. Chronic debilitating disease, e.g. chronic cardiovascular, pulmonary, renal, or metabolic
disorders.
2. Rheumatic heart disease, especially those with mitral stenosis.
3. Other cardiovascular disorders, especially those with evidence of frank or incipient cardiac
insufficiency.
4. Chronic bronchopulmonary disease, diabetes mellitus or Addison’s disease.
5. Pregnant women.
6. Persons in older age groups, those over 45 and, particularly, those over 65 years of age
who contribute most to excess mortality.Rev. Med. Virol. 9: 237–244 (1999)
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antigens may induce broader immune responses than
when they are contained in the intact virus particle.
Importantly, it was observed that children tolerated,
without local or febrile reaction, much larger doses of the
viral subunits than of whole virus. These materials
offer many potential advantages to wider application of
vaccine.
LIVE VIRUS VACCINE
It has long been recognised that live attenuated
influenza virus vaccine offers a potential advantage
over inactivated vaccine. Such a vaccine has been
developed through the process of adaptation at
suboptimal temperatures (25C), a technique described as
cold-adaptation.
The adaptation of influenza virus of type A and type B
to growth 25C has been found to be a reliable technique
for the development of attenuated viruses as candidates
for live virus vaccine for use in man.26–30 The extensive
experience acquired in our laboratory in the past 20 years
in the development of cold-adapted (ca) influenza virus
vaccine allows us to conclude that cold-adaptation using
recent human isolates can be considered a reliable
technique to attenuate influenza virus.31
Derivation of ‘Master’ strains for type A and
type B influenza virus
Domingo et al.32 emphasised that RNA viruses in general
exhibit a high degree of mutation and variability. For
example, influenza viruses exhibit antigenic variation
through either genetic reassortment with animal virus or
antigenic variation influenced by the host immune
response or by antiviral drugs. Thus, quasispecies with
changes in antigenic specificity may emerge which are
resistant to the selective pressure of the host necessitat-
ing periodic update of vaccines or changes in drug
regimen. Studies in our laboratories provided evidence
that temperature of incubation of infected cells can be a
factor in the alteration of virulence of mammalian viruses
grown in cell culture. Increased virulence of certainCopyright  1999 John Wiley & Sons, Ltd.viruses was correlated with their ability to grow at a
temperature above the physiological range (38–39C). In
contrast, adaptation of the virus to growth at suboptimal
temperature (25C) resulted in decreased virulence or
attenuation. Thus, virulence can be quantified and is a
quality that can be added or lost experimentally from a
virus strain.33,34 To develop an attenuated live influenza
virus vaccine we adapted influenza virus of type A or B
to grow to a maximum titre at 25C in cultures of
primary chick kidney cells and to derive ca mutants.34
The criteria for a candidate vaccine are listed in Table 2
and could be applied to any other viral pathogen of
human importance.
The process of cold-adaptation involved two different
processes. The first used stepwise adaptation of influenza
virus until a maximum titre at 25C was achieved. The
second procedure used direct passage of the virus from
the normal physiological temperature of 35–36C to the
suboptimal temperature of 25C (cold-adaptation) fol-
lowed by selection of the cold variant. The in vivo and in
vitro characterisation of the derived cold-adapted vari-
ants demonstrated that they were attenuated for humans,
were immunogenic and possess two markers, the ca and
ts phenotypes, which correlated with the loss of viru-
lence. The type A cold variant A/Ann Arbor/6/60-H2N2
and the type B influenza virus B/AA/1/66 upon admin-
istration intranasally to ferrets and to man were shed at
low levels in pharyngeal secretions, with no reversion or
transmission of the shed virus. Molecular characterisation
of these viruses based on the migration of the RNA
segments, using polyacrylamide gel electrophoresis,
showed that A/AA/6/60-H2N2 and B/AA/1/66 exhibited
changes in the migration of their segments, when com-
pared with the original unadapted segments, implying
that mutation(s) change in lesion(s) occurred upon cold-
adaptation, which can account for their genetic stability.
It is for this reason that the cold-adapted lines A/AA/6/
60-H2N2 B/Ann Arbor/1/66 were designated as the
‘Master’ strains or donor of all attenuating genes for use
in the derivation of cold-reassortant vaccine lines to be
used in man. However, the stepwise cold-adaptation
procedure was not practical for updating the live vaccines
in the event of shift or drift in the circulating viruses (6–8
months).33Table 2. Criteria for Candidate vaccine
1. A reliable and reproducible method of attenuation (e. g. cold-adaptation at 25C.
2. Availability of an animal model to evaluate pathogenicity prior to use in man (ferret model).
3. Availability of a marker system, the cold-adapted (ca) and the temperature-sensitive markers
(ts) to trace the vaccine in laboratory and field studies.
4. Non-transmissibility is an important factor from the point of view of minimising reversion
and the uncontrolled spread in the community.
5. Administration to man by the natural route of transmission (respiratory tract, nose drops).
6. Genetic stability, since live vaccine which has the potential to revert to virulence would not
be acceptable and would not be licensed for use in man.Rev. Med. Virol. 9: 237–244 (1999)
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cold-reassortant (CR) vaccine lines
Cold reassortants possessing the six internal genes from
the cold-adapted Master donor parent and the two
genes which code for the two surface glycoproteins of
the circulating wild type parent will be referred to in this
report as the 6/2 cold reassortant vaccine.31,33,34 Evalu-
ation of the 6/2 reassortant vaccines in an animal model
(ferrets) showed attenuation, immunogenicity and accept-
ability similar to their donor attenuated viruses (A/Ann
Arbor/6/60 and B/Ann Arbor/1/66). Thus, it can be stated
that laboratory criteria are available to identify, predict
and monitor the development and characterisation of live
influenza virus prior to administration to man (Table 3).
These laboratory criteria are offered for reproducibility
and rapidity of derivation of live influenza virus prior to
administration to man including the response to new
epidemic strains. In addition, gene analysis of these
vaccine candidates has allowed us to monitor the CR
during all phases of vaccine development from the
laboratory to the manufacturer to use in man as well as
for monitoring isolates from the field trials. The repro-
ducibility of these attenuated 6/2 reassortants can be
consistently achieved. For the past 12 years, these live
influenza virus cold reassortant vaccines, with HA and
NA genes from different wild type viruses, were proven
to be predictably attenuated for man, immunogenic, did
not spread to contacts, had varying degrees of potency inCopyright  1999 John Wiley & Sons, Ltd.seronegative and seropositive vaccinees and had genetic
stability demonstrated through retention of the ca and ts
phenotypes in all isolates obtained from trial in volun-
teers. In recent studies in volunteers, the efficacy of a live
attenuated cold reassortant influenza vaccine with a 6/2
gene composition was compared with a licensed inacti-
vated vaccine. The results were encouraging and showed
advantages (Table 4) of the live vaccine with regard to
lack of reactogenicity, natural route of administration and
protection upon wild type challenge.24,35,36
Studies of these influenza virus live cold reassortant
vaccines in seronegative children indicate that the trans-
fer of the six genes from the ‘Master strains’ A/Ann
Arbor/6/60-H2N2 or B/Ann Arbor/1/66 cold-adapted
parents to different wild type parents with relevant
surface antigens have reproducibly conferred significant
benefits. These include efficient infection, an acceptable
level of attenuation, significant protective response to
artificial or natural challenge, lack of transmissibility and
no evidence of reversion with retention of the ca and ts
phenotypes in the shed virus, implying genetic stability.
Nasal antibody and cell-mediated immunity was also
demonstrated. One of the potential advantages of an
attenuated live influenza virus vaccine derives from
limited replication in the infected host producing
adequate stimulation of both humoral and local secretory
immunoglobins (IgA) as well as cell-mediated immune
responses at the local site of viral administration.37Table 3. A flow diagram for the derivation of type A cold reassortant vaccine
Step 1. Wild type parent with relevant surface antigens was plaque-purified twice at 39C to
enhance its virulence and to achieve a genetic homogeneity of the virulent wild-type before
the reassortant procedure.
Step 2. The ‘Master’ strain cold-adapted A/AA/6/60-H2N2 7PI with three passages in SPAFAS
embryonated eggs is the attenuated parent.
Step 3. Co-infection in primary chick kidney cells (PCKC) with multiplicity of infection of 5 plaque-
forming units per mL for each parent—48 h incubation maximum cytolysis. The cultures
are frozen, thawed, centrifuged, and the supernatant was passaged.
Step 4. Passaged 2X at 33C in PCKC in presence of ferret immune serum to cold-adapted strain.
Step 5. Passaged 1X at 33C in PCKC in absence of ferret immune serum.
Step 6. Passaged 1X in SPAFAS embryonated hens’ eggs at 33C.
Step 7. Plaque titration at 33C in PCKC—selection of 20 clones for characterisation.
Step 8. Selection of a clone as a seed vaccine on the basis that six internal genes were derived from
the ‘Master’ strain.
Step 9. Plaque to plaque purification (3X) at 33C in PCKC.
Step 10. Passage in SPAFAS embryonated hens’ eggs for production of seed virus for distribution
and for production of volunteer pool.
Step 11. Choice of a cold-reassortant clone is based on
(i) having six genes from the ‘Master’ strain;
(ii) ts and ca markers;
(iii) no reactogenicity in ferrets.
Step 12. The procedure was modified for the derivation of type B cold-adapted reassortant vaccine
using the ‘Master’ strain B/Ann Arbor/1/66-7PI-SE3 by lowering the temperature at 25C
only during the whole process of cloning. This was necessitated by the similarities of sur-
face antigens of influenza B. Thus, the selection pressure provided by using a 25C incu-
bation temperature yielded not only a higher frequency in the derivation of 6/2 reassortant
vaccines but also shortened the time required by allowing us to screen 100 clones for the
appropriate vaccine line.Rev. Med. Virol. 9: 237–244 (1999)
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and co-workers showed for amnestic recall (induction of
memory) of influenza-specific IgA antibody in those
children with a wild type natural infection or in children
administered the attenuated live influenza A virus com-
pared with children with no prior experience of influ-
enza.38 Thus, both cell-mediated immunity (local) and
humoral antibodies appear to be mediators of immune
protection against influenza infection and disease. The
examples cited above emphasise that these live attenu-
ated CR vaccines offer an advantage by inducing both
types of antibodies, by minimising shedding and finally
by their inability to spread.
CURRENT STATUS
The current clinical trial programme being conducted by
Aviron in collaboration with the NIH is designed to
support application to the FDA for use of a new influenza
vaccine in children, adults, and the elderly.39 The product
is a trivalent formulation (two type A strains and one
type B strain) of the live, attenuated, cold-adapted
influenza vaccine (CAIV-T) delivered intranasally as a
spray. This vaccine provides an alternative to the inject-
able vaccine for healthy and high risk children and adults,
and could be co-administered with the injectable vaccine
in the elderly.
The live, attenuated, ca influenza vaccine technology
of H.F. Maassab was licensed to Aviron by the Univer-
sity of Michigan and NIH in 1995 after more than 90
clinical trials of ca vaccine strains had been were con-
ducted by the Vaccine Treatment and Evaluation Units
(VTEU) of the National Institute of Allergy and Infec-
tious Diseases (NIAID) of the NIH. More than 15 000
volunteers aged from 2 months to over 100 years
received monovalent or bivalent formulations of the
vaccine while trivalent formulations were tested in
approximately 350 adults and 200 children. The results of
these clinical trials consistently showed that the ca
vaccine was safe and well tolerated, immunogenic,
genetically stable, and non-transmissible. Efficacy of the
monovalent and bivalent formulations of the ca vaccine
were demonstrated in multiple experimental challengeCopyright  1999 John Wiley & Sons, Ltd.studies and in clinical field trials, including the Vanderbilt
study which was conducted over four influenza seasons
from 1986 to 1990 in 5000 children and adults.40
Aviron and the NIH initially conducted a double blind,
placebo controlled study of CAIV-T to demonstrate
efficacy of the intranasal trivalent formulation in healthy
adults.41 Volunteers were randomised to receive either
CAIV-T, the inactivated injectable vaccine, or placebo
and then challenged one month later with the wildtype
influenza virus to which they had originally been shown
to be seronegative. The reduction in laboratory-
documented influenza illness due to the wildtype H1N1,
H3N2 or B strains compared with placebo was statisti-
cally significant for CAIV-T, 85% (P=0.001), and the
injectable vaccine, 71% (P=0.01).
Following routine testing of the intranasal CAIV-T
vaccine for safety, immunogenicity, and determination of
dose in children,41 Aviron and the NIH conducted a
multicentre, randomised, double-blind, placebo-controlled
field efficacy trial in 1602 children, 17–71 months old
during the 1996–97 influenza season. The efficacy
against A/H3N2 was 95% and the efficacy against
influenza B was 91%. In addition, there was a 30%
reduction in febrile otitis media in the children vaccinated
with CAIV-T.42,43.
Of the 1602 children enrolled in year one of the study,
1358 returned in year two (1997–98 influenza season).
They remained in their randomised groups and were
vaccinated with a single dose of CAIV-T or a placebo
spray. Results from the second year of the double-blind,
placebo-controlled efficacy study showed that CAIV-T
provided 87% protection against all culture-confirmed
influenza including the A/Sydney strain which was not in
the vaccine. The A/Sydney influenza strain was not
included in the 1997–98 formulation because CAIV-T
was designed to match the influenza vaccine marketed
that year. In the 1358 participants, there were 5 cases of
influenza due to influenza strains included in the vaccine
and 66 cases caused by the A/Sydney strain. Only 2% of
children vaccinated with CAIV-T (15 out of 917) experi-
enced culture-confirmed influenza, all of which was
attributable to the A/Sydney strain, while 13% of the
placebo recipients (56 out of 441) experienced culture-
confirmed influenza. The difference between these twoTable 4. Advantages of the cold-adaptation methods in the development of live influenza virus
vaccines for man
1. Availability of laboratory guidelines for assessment of virulence.
2. Availability of cold-adapted ‘Master Strain’ A/AA/6/60-H2N2 and B/AA/1/66 as donors of
attenuated genes.
3. Rapidity in the development of cold reassortant clones with the desired gene constellation.
4. Presence of ts and ca markers.
5. Genetic stability.
6. Reproducibility in attenuation and immunogenicity for man.
7. Lack of transmission.Rev. Med. Virol. 9: 237–244 (1999)
LIVE INFLUENZA VIRUS VACCINE 243influenza attack rates was used to calculate the overall
protection rate of 87%. The incidence of pneumonia and
other lower respiratory diseases was also reduced in the
vaccinees, compared with placebo recipients. Eight chil-
dren in the placebo group developed influenza-related
wheezing, bronchitis or pneumonia. All of these were due
to the A/Sydney strain. No children who received
CAIV-T experienced lower respiratory complications.
The year two data also showed that CAIV-T provided
94% protection against influenza-related otitis media (2
cases in the vaccine group vs. 17 cases in the placebo
group).43.
Because the ca influenza vaccine is delivered as a nasal
spray, it should provide the first practical way to immu-
nise children on an annual basis. Children are an import-
ant target because, while the elderly experience the
greatest mortality from the annual influenza epidemic,
much of the morbidity and illness occurs in young
children. Children are also thought to be important to the
spread of influenza in the population. In addition to its
proposed use in physician(s) offices, the nasal delivery of
this vaccine should enable it to be administered by adults
without special medical training, so that it will be
practical to consider delivery in pharmacies, schools, day
care centres, and possibly in the home.
Clinical trials to obtain effectiveness data in healthy
working adults, and safety data in asthmatic children are
in progress. Additional trials are planned for the 1998–99
influenza season to study herd immunity in children and
efficacy of co-administration with injected influenza
vaccine in high risk adults.
Of interest, a novel method that uses the reverse
genetics4445 technology to generate the vaccine strains
each year (6:2 reassortants) has recently been devel-
oped45. It is now possible to selectively introduce the HA
and NA gene segments of wild type influenza A or B
virus directly into the cold-adapted A and B master
strains without in vitro propagation of wild type influenza
virus. This method should significantly shorten the time
required to prepare 6:2 reassortants for the annual
vaccine and improve reliability of the reassortment pro-
cess by eliminating gene dominance that can occur using
traditional methods. The antigenicity of the vaccine
viruses prepared using classical methods, and the nucleo-
tide sequence of the HA and NA genes match the HA
and NA of their respective wildtype influenza virus
strains from which they were obtained. Vaccine contain-
ing a recombinant reassortant has been shown to be
safe and well tolerated in a single study in children and
adults. Additional safety and immunogenicity of vaccine
virus prepared using the recombinant methodology is
currently under investigation.
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